Background Head-to-head randomized studies comparing ixekizumab and secukinumab in the treatment of psoriasis are not available. Objectives To assess efficacy and quality of life using matching-adjusted indirect comparisons for treatment with ixekizumab vs. secukinumab. Methods Psoriasis Area and Severity Index (PASI) improvement of at least 75%, 90% and 100% and Dermatology Life Quality Index (DLQI) 0/1 response rates for approved dosages of ixekizumab (160 mg at Week 0, then 80 mg every two weeks for the first 12 weeks) and secukinumab (300 mg at Weeks 0, 1, 2, 3 and 4, then 300 mg every 4 weeks) treatment were compared using data from active (etanercept and ustekinumab) and placebo-controlled studies. Comparisons were made using the Bucher (BU) method and two modified versions of the Signorovitch (SG) method (SG total and SG separate). Subsequently, results based on active treatment common comparators were combined using generic inverse-variance meta-analysis. Results In the meta-analysis of studies with active comparators, PASI 90 response rates were 12Á7% [95% confidence interval (CI) 5Á5-19Á8, P = 0Á0005], 10Á0% (95% CI 2Á1-18Á0, P = 0Á01) and 11Á2% (95% CI 3Á2-19Á1, P = 0Á006) higher and PASI 100 response rates were 11Á7% (95% CI 5Á9-17Á5, P < 0Á001), 12Á7% (95% CI 6Á0-19Á4, P < 0Á001) and 13Á1% (95% CI 6Á3-19Á9, P < 0Á001) higher for ixekizumab compared with secukinumab using BU, SG total and SG separate methods. PASI 75 results were comparable when SG methods were used and favoured ixekizumab when the BU method was used. Week 12 DLQI 0/1 response rates did not differ significantly. Conclusions Ixekizumab had higher PASI 90 and PASI 100 responses at week 12 compared with secukinumab using adjusted indirect comparisons.
Introduction
During the past few decades, biologics have revolutionized the treatment of moderate-to-severe psoriasis, with higher efficacy and less organ toxicity than most of the conventional treatments. 1 Interleukin (IL)-17A has been shown to be a key cytokine in psoriasis pathogenesis, and recently, biologics targeting IL-17A have provided rapid improvement of psoriasis with high levels of skin clearance maintained over time and manageable safety profiles in phase III trials. [2] [3] [4] [5] [6] [7] [8] Reliable evidence on the comparative efficacy of two currently approved IL-17A antagonists, namely ixekizumab and secukinumab, which have both demonstrated superiority to placebo, etanercept and ustekinumab in randomized clinical trials, 2-8 may help to inform clinical and economic decisions regarding their use. In the absence of head-to-head trials, indirect comparisons through a common comparator provide a good approach to understanding the differences between these two treatments. 9 Although an indirect comparison is not a replacement for a head-to-head trial, accuracy is improved when a common active comparator is used with a method such as the previously described matching-adjusted indirect comparison (MAIC), which combines published and patient-level data that are matched for baseline characteristics. 9 Because the MAIC uses individual patient data (IPD), this approach is complementary to and can reduce biases found in network meta-analyses (NMAs), which have limitations that have been described elsewhere. [10] [11] [12] [13] Matching on baseline characteristics helps to reduce imbalances from different trials that might impact the outcome (treatment effect modifiers). 9 Thus, if IPD is available and there is an imbalance regarding known effect modifiers that may impact the results across trials (especially across IPD and published trials), MAICs might be preferred over adjusted indirect comparisons (AICs) or NMAs.
In this report, we indirectly compared efficacy and quality of life during the first 12 weeks of treatment with ixekizumab vs. secukinumab, using the MAIC method for phase III trials of patients with moderate-to-severe plaque psoriasis that included placebo, etanercept and/or ustekinumab (common comparators). Specifically, this method calculated weights for the patients treated with ixekizumab, for which we have patient-level data available, to match for the average baseline characteristics and/or treatment effect modifiers reported for patients treated with secukinumab (such as duration of psoriasis, previous systemic therapy and baseline weight), which could introduce bias resulting from imbalances across trials, and then applied those weights to the outcomes of interest. Finally, the weighted outcomes for patients treated with ixekizumab were used along with the outcomes from the patients treated with secukinumab for the calculation of the adjusted indirect comparison. 9 
Materials and methods
Inclusion and exclusion criteria for UNCOVER-1 (NCT0 1474512), UNCOVER-2 (NCT01597245), UNCOVER-3 (NC T01646177), IXORA-S (NCT02561806), ERASURE (NCT0 1365455), FIXTURE (NCT01358578), FEATURE (NCT01555125), JUNCTURE (NCT01636687) and CLEAR (NCT02074982) trials have been previously reported. [2] [3] [4] [5] [6] [7] [8] Common inclusion criteria for these studies included patients aged ≥ 18 years, a diagnosis of chronic plaque psoriasis ≥ 6 months prior to randomization, and psoriasis that was moderate-to-severe at randomization. At week 12, Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 end points at week 12 were analysed using nonresponder imputation (NRI) in all studies. Quality of life was assessed using Dermatology Life Quality Index (DLQI) 0/1 status and missing data were imputed using the last observation carried forward (LOCF) for all studies, as primary secukinumab studies reported LOCF and not NRI.
Systematic literature review for previous network metaanalyses
Clinical efficacy and safety data of potential ixekizumab comparators for the treatment of moderate-to-severe plaque psoriasis were identified through an independent systematic review (the results of which have been previously reported) 10 Search strategy and selection criteria for updated search, specifically for secukinumab studies
Patient-level data were available for all ixekizumab studies, which are described below. To obtain aggregate data for secukinumab studies and check for any new studies since the previous search, an SLR of MEDLINE and Cochrane were carried out and updated in March 2017. The search terms were 'secukinumab' AND 'psoriasis' AND 'trial'. Reference lists were combined and duplicates were removed. Reviews, metaanalyses and abstracts that contained duplicate data from the primary manuscript were removed, as were disclosures with secondary analyses outside of the outcomes of interest. The following inclusion criteria were applied: (i) randomized, double-blind, phase III trial; (ii) either placebo or active control arm; (iii) moderate-to-severe plaque psoriasis (overall, no subgroups); and (iv) secukinumab treatment.
Exclusion criteria
Manuscripts/abstracts were excluded if they reported outcomes for only a subgroup of patients with moderate-tosevere psoriasis in the trial based on body region (e.g. nails, scalp, palmoplantar). A Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram is provided in Figure S1 (see Supporting Information).
Outcome measures extracted
AIC of the U.S. Food and Drug Administration (FDA)-approved dosages for the first 12 weeks of treatment [ixekizumab (160 mg at week 0, then 80 mg every 2 weeks) and secukinumab (300 mg at weeks 0, 1, 2, 3 and 4, then 300 mg every 4 weeks)] relative to the common comparators etanercept 50 mg twice weekly, weight-based dosing of ustekinumab, and placebo, were conducted using the standard methods for indirect comparisons described by Bucher et al.
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(BU) and a modified version of the Signorovitch (SG) method (balanced or weighted per treatment arm separately vs. overall as with original SG method), 9 which adjusts for respective baseline differences and/or any treatment effect modifiers. The SG comparison was carried out by calculating weights for the IPD based on mean values of covariates for total population (SG total) and on mean values of covariates for each treatment arm separately (SG separate). The weights were calculated in order to balance baseline characteristics/effect modifiers across studies (File S1; see Supporting Information). Calculated weights were then applied to the outcomes for the IPD and the AIC, which were calculated based on the weighted outcome for the IPD. For studies using etanercept as the common comparator, variables used for the weight calculation included age, sex, weight, duration of psoriasis, body surface area (BSA), psoriatic arthritis (PsA) and previous systemic psoriasis therapy; all of these variables except for PsA were used for studies where placebo was the common comparator (this variable was not available for all placebo-controlled studies). For studies where ustekinumab was the common comparator, age, sex, weight, duration of psoriasis, BSA, PsA, previous systemic psoriasis therapy and previous biological treatment failure were used. Variables were chosen based on the overlap for studies using the same comparator. Additional sensitivity analyses were conducted where BSA and weight were replaced by PASI and body mass index (BMI).
Two patients treated with placebo from the UNCOVER trials were excluded from the MAIC approach owing to missing data for baseline weight and three patients were excluded owing to missing data for baseline BMI. Additionally, one patient from the ixekizumab Q2W group was excluded for missing data for baseline BMI. Furthermore, for the IXORA-S study, one patient from the ustekinumab arm had missing data for baseline BSA.
The BU-adjusted indirect comparison method utilized the same patient population as the MAIC approach. Bootstrap estimates with 1000 iterations were used to calculate the variance of the weighted estimator in the SG comparison. This variance was used to calculate P-values and confidence intervals (CIs). 17 Risk difference (RD) and odds ratios (ORs) with associated 95% CI are presented below. Using the ixekizumab vs. secukinumab AIC, a meta-analysis was performed for the results from the MAIC using frequentist random and fixed effects meta-analyses. All statistical analyses were conducted using R version 3.2.4.
18 Placebo results were included as a sensitivity analysis.
Results
Selected baseline characteristics prematch and postmatch are reported in Table 1 . Figure 1 
Risk differences
Generally, relative PASI responses at week 12 were higher for ixekizumab compared with secukinumab. In the combination of results from all trials with active comparators via meta-analysis, week-12 PASI 75 RDs were modestly higher for ixekizumab vs. secukinumab for all methods used; however, only the BU method demonstrated statistical significance (Fig. 2a) . When evaluating the combination of results from all trials with active comparators, week-12 PASI 90 (10-12Á6%) and PASI 100 (11Á7-13Á1%) RDs were statistically significantly higher (P < 0Á05) for ixekizumab vs. secukinumab for all methods used (Fig. 2b, c) . RD results were even more favourable for ixekizumab when placebo was used as the common comparator ( Fig. S2a; see Supporting Information).
Odds ratios
In the combination of results from all trials with active comparators, PASI 75 ORs favoured ixekizumab compared with secukinumab with a statistical significance of P < 0Á05 for all methods (Fig. 3a) . PASI 90 ORs also favoured ixekizumab; however, statistical significance (P < 0Á05) was observed only when using the BU and SG separate methods (Fig. 3b) . PASI 100 ORs favoured ixekizumab, but not significantly (Fig. 3c) . ORs for all relative PASI outcomes using placebo as the common comparator ratios favoured ixekizumab, but only demonstrated statistical significance for PASI 75 when the BU method was used ( Fig. S2b; see Supporting Information).
Similar OR and RD results for all relative PASI outcomes were observed in sensitivity analyses with each common comparator when matched for different baseline characteristics.
In the meta-analysis of results from studies with active comparators, RDs for DLQI 0/1 responses were generally similar between ixekizumab and secukinumab, although they were numerically higher for ixekizumab when analysed using the BU method (Fig. 2d) . A similar pattern was seen for ORs (Fig. 3d) .
Discussion
In the absence of head-to-head randomized trials comparing the relative efficacy of ixekizumab vs. secukinumab, the SG MAIC method, 9 which adjusts for differences in baseline clinical characteristics and observed treatment effect modifiers across studies, may provide a less biased approach to the widely used and accepted AIC approach described by Bucher et al. 16 After adjusting for cross-trial differences in baseline characteristics, ixekizumab (UNCOVER-1, UNCOVER-2 and UNCOVER-3, and IXORA-S) was associated with significantly higher percentages of patients achieving clear or nearly clear skin (PASI 90 and PASI 100) compared with secukinumab (FIXTURE, ERASURE, JUNC-TURE, FEATURE and CLEAR) at week 12 among patients with moderate-to-severe psoriasis.
In the present meta-analysis, treatment of patients with moderate-to-severe psoriasis with either ixekizumab or secukinumab achieved high PASI 75 response rates with small differences when adjusting for baseline clinical characteristics and/or treatment effect modifiers. Both before and after adjusting for baseline characteristics and/or treatment effect modifiers, PASI 90 and PASI 100 response rates were significantly higher for ixekizumab vs. secukinumab via etanercept. Across the different PASI end points, ixekizumab tended to provide a more rapid onset of action. This may be valuable to many patients with psoriasis, as surveys indicate that rapid improvement of disease and clearance of skin lesions are important treatment goals. 19, 20 Interestingly, although there were significant differences in skin resolution at week 12, the proportion of patients for whom psoriasis had little or no impact on health-related quality of life was similar for ixekizumab and secukinumab. This was somewhat unexpected given previous reports of associations between skin clearance and quality of life. based on U.S. pricing, monthly cost per additional PASI 100 responder was lowest in patients treated with ixekizumab vs. patients treated with secukinumab or other biologics.
14 A comparison of safety data was not performed because most adverse events were either too rare, potentially defined by different criteria, or potentially analysed via different methods in the different trials. In addition, meaningful safety comparisons would require long-term follow-up, which is challenging because most ixekizumab and secukinumab studies have different trial designs beyond 12 weeks. It is also possible that differences existed across trials in terms of how adverse events were collected (e.g. active vs. passive elicitation) and in the definition of 'treatment-emergent'. 24 It is important to note that the PASI results were based on the nonresponder imputation, in which all patients who discontinued the study for any reason including adverse events were counted as nonresponders. Thus, the PASI results already combine elements of efficacy and tolerability. This study has several limitations. Even when matching on baseline characteristics and/or effect modifiers, and using an active comparator (etanercept or ustekinumab) to make relative comparisons, differences in trial populations, designs and conduct, along with the potential presence of unmeasured confounders may remain and can influence treatment effects; these issues are less likely to affect treatment comparisons within a head-to-head randomized trial. Although this comparison shows higher responses earlier for ixekizumab compared with secukinumab, peak responses for each drug may occur at different time points. UNCOVER trials have sufficiently different study designs compared with FIXTURE, ERA-SURE and JUNCTURE making longer-term comparisons beyond 12 weeks difficult. IXORA-S and CLEAR designs are more similar, but these trials are also significantly smaller, increasing the uncertainty of the indirect comparisons based only on these studies. Application of the SG or of the modified SG approach usually leads to a reduction of effective sample sizes and thus wider CIs. 9 Matching is dependent on aggregate data, and therefore varies by study. The approach of performing a meta-analysis of several MAIC networks might provide a more robust and reliable effect estimate. However, this approach is new and more research is necessary to investigate its strengths and limitations fully. This study also has several strengths. Active comparators (etanercept or ustekinumab), which are more informative than a placebo, were used in addition to placebo as common comparators for the indirect comparison. Placebo response rates (especially for PASI 90 or PASI 100) are very low (nearly zero) across studies and are therefore noninformative with respect to variations in study design, and low responses in this group make CIs around the ORs unstable and difficult to interpret. Baseline differences between studies are one of the main challenges when using indirect comparisons, and using the modified SG approach allows us to reduce treatment differences that are attributable to differences in baseline characteristics. In the field of psoriasis, trials across compounds have similar inclusion and exclusion criteria, reporting of baseline characteristics and analyses of treatment effects, which allows for this approach to be used. Finally, the combined studies included large sample sizes allowing for a good estimation of the treatment difference between ixekizumab and secukinumab.
This study provides evidence via indirect comparison to support the higher efficacy of ixekizumab compared with secukinumab through 12 weeks of treatment in patients with moderate-to-severe psoriasis with regard to PASI 90 and PASI 100 (RDs) and PASI 75 and PASI 90 (ORs). Even with adjustment for cross-trial differences in baseline characteristics and treatment effect modifiers, ixekizumab was associated with higher relative PASI responses compared with secukinumab. Notably, the results of this study showed a rapid onset of action with higher percentages of patients treated with ixekizumab achieving higher levels of clearance (PASI 90) at week 2 compared with patients treated with secukinumab, both of which are important patient preferences in biological treatment. 19, 20 
